NASDAQ:DEPO Depomed (DEPO) Stock Price, News & Analysis → #1 election stock (From Porter & Company) (Ad) Free DEPO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$7.09▼$7.4250-Day Range N/A52-Week Range$4.31▼$9.48Volume940,193 shsAverage Volume1.30 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Depomed alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Depomed Stock (NASDAQ:DEPO)Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.Read More Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 DEPO Stock News HeadlinesOctober 30, 2023 | finance.yahoo.comVulvodynia Treatment Market Size and Growth Analysis | Future Trends Analysis and Revenue Status 2023-2030August 29, 2023 | thestreet.comHorizon Pharma (HZNP) Stock Sinks After DepoMed Rejects Unsolicited $3 Billion BidMay 1, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”August 13, 2023 | thestreet.comWhy DepoMed (DEPO) Stock Is Gaining TodayJuly 31, 2023 | finance.yahoo.comSurge in Chronic Disorders Fuels Expansion of Global Tapentadol Market, Projected to Hit USD 5.32 Billion by 2028July 8, 2023 | thestreet.comOpioid Litigants Get Boost From Senate ReportMay 17, 2023 | marketwatch.comChronic Fatigue Syndrome Therapeutics Drug Market Till 2030May 12, 2023 | marketwatch.comPain Management Market Size, Outlook, Trends, Share by 2030May 1, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”May 11, 2023 | marketwatch.comGlobal Neuropathy Pain Treatment Market [2023] | Industry Set to Expand with Strong 3.4% CAGR and Reach USD 10560 Million by 2030May 10, 2023 | msn.comHow Turkey's opposition is taking the taboo out of the headscarf debateApril 29, 2023 | marketwatch.comGlobal Gabapentin Market by Size, Scope 2023: with Development Status 2031April 23, 2023 | marketwatch.com2023-2030 Chronic Pain Management Drugs Market Size with Manufactures and Upcoming OpportunitiesApril 17, 2023 | thestreet.comDepomed, Insys Shares Down After FDA Decision on Endo's Opana ERApril 15, 2023 | marketwatch.comPeripheral Neuritis Treatment research report leads towards the developing of this industry with an estimated CAGR 11.1% during 2023-2030April 13, 2023 | marketwatch.comNeuropathy Pain Treatment Market Growth Prediction and Segment Insight 2023-2107April 5, 2023 | marketwatch.comNeuropathy Pain Treatment Market 2023 Size and Forecast to 2031March 30, 2023 | marketwatch.comVulvodynia Treatment Market: Overview of the Regional Outlook 2023-2030March 14, 2023 | marketwatch.comPain Management Market Size, Growth | Soaring Demand | 2023 - 2029March 13, 2023 | marketwatch.comPain Relief Medications Market Research Report 2023-2028 with Top Countries DataFebruary 21, 2023 | marketwatch.comDiabetic Neuropathy Treatment Market 2023 Exploring New Challenges and Opportunities, Forecast to 2028February 3, 2023 | marketwatch.comControlled Release Drug Delivery Market 2023 Expected to Reach Significant Rate by 2029January 29, 2023 | marketwatch.comNeuropathy Pain Treatment Market Growth, Size, Share, Opportunities, Industry Analysis and Forecast 2023 To 2028January 23, 2023 | thestreet.comCFO Says Depomed to Buy or Be SoldJanuary 3, 2023 | marketwatch.comNeuropathic Pain Management Market Size, Share and Forecast 2028 with Top Countries DataOctober 15, 2022 | newsweek.comJ.D. Vance Cancels Fundraiser Planned by Doctor Mentioned in Opioid Lawsuit - NewsweekOctober 12, 2022 | marketwatch.comPain Management Drugs Market is Growing Worldwide | 133 Report PagesSee More Headlines Receive DEPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Depomed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2018Today5/01/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DEPO CUSIP24990810 CIK1005201 Webwww.depomedinc.com Phone(224) 419-7106FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDaniel A. PeisertPresident, Chief Executive Officer & DirectorPaul SchwichtenbergChief Financial Officer & Senior Vice PresidentAjay PatelChief Accounting Officer & Senior Vice PresidentMegan C. TimminsSecretary, Senior Vice President & General CounselMax NemmersHead-Investor Relations & AdministrationKey CompetitorsContext TherapeuticsNASDAQ:CNTXLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors DEPO Stock Analysis - Frequently Asked Questions How were Depomed's earnings last quarter? Depomed, Inc. (NASDAQ:DEPO) posted its quarterly earnings data on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.03. The specialty pharmaceutical company had revenue of $63.27 million for the quarter, compared to analysts' expectations of $63.72 million. Depomed's quarterly revenue was down 37.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 earnings per share. What other stocks do shareholders of Depomed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Vertex Pharmaceuticals (VRTX), MercadoLibre (MELI), Alphabet (GOOG), Horizon Therapeutics Public (HZNP), Bausch Health Companies (BHC), Gilead Sciences (GILD), Allergan (AGN) and Bristol-Myers Squibb (BMY). This page (NASDAQ:DEPO) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTracker#1 election stockPorter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBiden out June 13; Kamala won’t replace him?Paradigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Depomed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
